New allergy shot aims to tame mugwort season in just four weeks
NCT ID NCT07563439
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This Phase 2 trial tests PollenVax, a new immunotherapy for people with moderate-to-severe allergic rhinitis caused by mugwort pollen. The treatment is given as four weekly shots before the pollen season. Researchers will compare symptom scores and medication use between the PollenVax groups and a placebo group. The goal is to see if this ultra-short regimen can safely ease seasonal allergy symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PollenVax (recombinant mugwort allergen Art v 1 with adjuvant Montanide ISA-51)
- What this could lead to
- If successful, this could lead to a convenient, ultra-short treatment course that reduces allergic rhinitis symptoms and the need for daily allergy medications during mugwort pollen season.
- What could go wrong
- This is an early Phase 2 trial with only 138 participants, so results may not apply to everyone. The treatment may cause injection site reactions or fail to outperform placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHINITIS, ALLERGIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Limited Liability Partnership "Medcenter-Rakhat"
RECRUITINGAlmaty, Almaty, 050010, Kazakhstan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Antiviral drug ganciclovir explored as new weapon against stubborn allergies
- New nasal spray shows promise for ragweed allergy sufferers
- SNIFF TEST: nasal swab may reveal lung disease severity
- New study checks allergy Pill's safety and symptom relief
- New allergy shots show promise for dust mite sufferers
- New allergy vaccine shows promise in early safety trial